DK0687181T3 - Metode til behandling af hepatitis C hos individer, som ikke responderer på interferon-behandling - Google Patents

Metode til behandling af hepatitis C hos individer, som ikke responderer på interferon-behandling

Info

Publication number
DK0687181T3
DK0687181T3 DK94910226T DK94910226T DK0687181T3 DK 0687181 T3 DK0687181 T3 DK 0687181T3 DK 94910226 T DK94910226 T DK 94910226T DK 94910226 T DK94910226 T DK 94910226T DK 0687181 T3 DK0687181 T3 DK 0687181T3
Authority
DK
Denmark
Prior art keywords
individuals
respond
treating hepatitis
interferon therapy
hepatitis
Prior art date
Application number
DK94910226T
Other languages
Danish (da)
English (en)
Inventor
Paul B Chretien
Milton Mutchnick
Original Assignee
Alpha 1 Biomedicals Inc
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/027,500 external-priority patent/US6001799A/en
Application filed by Alpha 1 Biomedicals Inc, Univ Wayne State filed Critical Alpha 1 Biomedicals Inc
Application granted granted Critical
Publication of DK0687181T3 publication Critical patent/DK0687181T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK94910226T 1993-03-05 1994-03-03 Metode til behandling af hepatitis C hos individer, som ikke responderer på interferon-behandling DK0687181T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/027,500 US6001799A (en) 1991-09-13 1993-03-05 Method of treating hepatitis C in non-responders to interferon treatment
PCT/US1994/002320 WO1994020131A1 (en) 1993-03-05 1994-03-03 Method of treating hepatitis c in non-responders to interferon treatment

Publications (1)

Publication Number Publication Date
DK0687181T3 true DK0687181T3 (da) 2001-10-01

Family

ID=21838079

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94910226T DK0687181T3 (da) 1993-03-05 1994-03-03 Metode til behandling af hepatitis C hos individer, som ikke responderer på interferon-behandling

Country Status (17)

Country Link
EP (1) EP0687181B1 (de)
JP (1) JPH06279309A (de)
KR (1) KR100306024B1 (de)
CN (1) CN1072961C (de)
AT (1) ATE204760T1 (de)
AU (1) AU683248B2 (de)
CA (1) CA2157479C (de)
DE (1) DE69428112T2 (de)
DK (1) DK0687181T3 (de)
ES (1) ES2162862T3 (de)
FI (1) FI954127A7 (de)
GR (1) GR3037021T3 (de)
MY (1) MY121198A (de)
NO (1) NO320877B1 (de)
PT (1) PT687181E (de)
SG (1) SG64894A1 (de)
WO (1) WO1994020131A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2214551T3 (es) 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
CA2418154A1 (en) * 2000-08-07 2002-02-14 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis c with thymosin and pegylated interferon
JP4629033B2 (ja) 2003-03-28 2011-02-09 サイクローン・ファーマシューティカルズ・インコーポレイテッド チモシンα１によるアスペルギルス感染の治療
JP5441685B2 (ja) * 2006-05-02 2014-03-12 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ チモシンα１の、単独またはＰＴＸ３またはガンシクロビルとの組合せにおける、サイトメガロウイルス感染の処置のための使用
US9034837B2 (en) * 2009-04-24 2015-05-19 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
JP2012526149A (ja) 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
TW224053B (de) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
AU683248B2 (en) 1997-11-06
AU6275994A (en) 1994-09-26
FI954127L (fi) 1995-09-04
ES2162862T3 (es) 2002-01-16
EP0687181A1 (de) 1995-12-20
FI954127A0 (fi) 1995-09-04
DE69428112T2 (de) 2002-03-21
NO953473L (no) 1995-09-04
CA2157479C (en) 2000-08-08
KR960700741A (ko) 1996-02-24
MY121198A (en) 2006-01-28
PT687181E (pt) 2002-01-30
NO320877B1 (no) 2006-02-06
CA2157479A1 (en) 1994-09-15
WO1994020131A1 (en) 1994-09-15
DE69428112D1 (de) 2001-10-04
NO953473D0 (no) 1995-09-04
CN1092322A (zh) 1994-09-21
GR3037021T3 (en) 2002-01-31
KR100306024B1 (ko) 2001-11-30
EP0687181B1 (de) 2001-08-29
SG64894A1 (en) 1999-05-25
FI954127A7 (fi) 1995-09-04
JPH06279309A (ja) 1994-10-04
CN1072961C (zh) 2001-10-17
ATE204760T1 (de) 2001-09-15

Similar Documents

Publication Publication Date Title
DE60142776D1 (de) Behandlung von herpes infektion mit anwendung von immunomodulatore polynukleotide sequenzen
DK0603305T3 (da) Anvendelse af et thymosin til behandling af hepatitis C
WO2001068077A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections
DE69636734D1 (de) Nucleoside mit anti-hepatitis b virus wirksamkeit
MY133891A (en) Polyethylene glycol modified interferon therapy
DE69233607D1 (de) Peptide, die die zytotoxische T-Lymphozyte Antwort gegen Hepatitis-B-Virus induzieren
EP0616535A4 (de) Methode zur behandlung von varalen infektionen.
FI954127A0 (fi) Menetelmä C-hepatiitin hoitamiseksi interferonihoitoon reagoimattomissa potilaissa
AR036697A1 (es) Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
BR9913951A (pt) Tratamento de infecção de hepatite b com timosina alfa 1 em combinação com lamivudina e flamciclovir
AR036698A1 (es) Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
CY1106388T1 (el) Θepαπεια ηπατιτιδας c με θυμοσινη, ιντepφepονη και ριβαβιρινη
NO950599L (no) Fremgangsmåte for inhibering av HIV-replikasjon ved anvendelse av IL-4
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
DK0531341T3 (da) Anvendelse af leukoregulin til behandling af dyr, der er inficeret med et kappevirus
NO930401D0 (no) Peptider som blokkerer hiv-infeksjoner og metoder for bruk derav
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
EP1143981A4 (de) Behandlung und vorbeugung von hiv- und anderen virus infektionen
BR112022006913A2 (pt) Métodos para tratar infecções virais de hepatite delta
ECSP982492A (es) Terapia de interferones polietilenglicol, modificados